1. Home
  2. RCEL vs JHS Comparison

RCEL vs JHS Comparison

Compare RCEL & JHS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RCEL
  • JHS
  • Stock Information
  • Founded
  • RCEL N/A
  • JHS 1973
  • Country
  • RCEL United States
  • JHS United States
  • Employees
  • RCEL N/A
  • JHS N/A
  • Industry
  • RCEL Medical/Dental Instruments
  • JHS Finance Companies
  • Sector
  • RCEL Health Care
  • JHS Finance
  • Exchange
  • RCEL Nasdaq
  • JHS Nasdaq
  • Market Cap
  • RCEL 140.5M
  • JHS 131.4M
  • IPO Year
  • RCEL N/A
  • JHS N/A
  • Fundamental
  • Price
  • RCEL $5.33
  • JHS N/A
  • Analyst Decision
  • RCEL Strong Buy
  • JHS
  • Analyst Count
  • RCEL 4
  • JHS 0
  • Target Price
  • RCEL $13.75
  • JHS N/A
  • AVG Volume (30 Days)
  • RCEL 267.6K
  • JHS 32.8K
  • Earning Date
  • RCEL 11-06-2025
  • JHS 01-01-0001
  • Dividend Yield
  • RCEL N/A
  • JHS 3.96%
  • EPS Growth
  • RCEL N/A
  • JHS N/A
  • EPS
  • RCEL N/A
  • JHS 0.02
  • Revenue
  • RCEL $74,884,000.00
  • JHS N/A
  • Revenue This Year
  • RCEL $22.92
  • JHS N/A
  • Revenue Next Year
  • RCEL $37.07
  • JHS N/A
  • P/E Ratio
  • RCEL N/A
  • JHS $553.50
  • Revenue Growth
  • RCEL 38.32
  • JHS N/A
  • 52 Week Low
  • RCEL $3.60
  • JHS $9.76
  • 52 Week High
  • RCEL $14.16
  • JHS $11.25
  • Technical
  • Relative Strength Index (RSI)
  • RCEL 49.55
  • JHS 57.40
  • Support Level
  • RCEL $5.14
  • JHS $11.76
  • Resistance Level
  • RCEL $5.61
  • JHS $12.08
  • Average True Range (ATR)
  • RCEL 0.24
  • JHS 0.14
  • MACD
  • RCEL -0.03
  • JHS 0.00
  • Stochastic Oscillator
  • RCEL 41.94
  • JHS 51.06

About RCEL Avita Medical Inc.

Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in rollout across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.

About JHS John Hancock Income Securities Trust

John Hancock Income Securities Trust is a United States-based closed-ended diversified management investment company. Its primary objective is to generate a high level of current income consistent with prudent investment risk. The fund invests its net assets (plus borrowings for investment purposes) in income securities, consisting of marketable corporate debt securities, governmental obligations, and cash and commercial paper. A majority of its net assets are invested in debt securities that are rated, at the time of acquisition, investment-grade or in unrated securities determined by the Fund's investment advisor or subadvisor to be of comparable credit quality.

Share on Social Networks: